Healthpeak Properties stock (US42226K1051): analyst moves and solid earnings support 2026 rally

Healthpeak Properties shares have climbed in 2026 as the healthcare REIT beat first?quarter expectations and drew fresh analyst attention, including a higher price target from Baird and a rating change at Evercore ISI.

Healthpeak Properties has drawn fresh attention from Wall Street after a recent earnings beat and new analyst commentary, while the stock continues to trade near the upper end of its 52?week range on the New York Stock Exchange. The healthcare?focused real estate investment trust recently reported quarterly funds from operations ahead of expectations and saw Baird lift its price target, even as Evercore ISI shifted to a more neutral stance, according to MarketBeat as of 05/15/2026 and Insider Monkey as of 05/13/2026.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Healthpeak Properties, Inc.
• Sector/industry: Healthcare real estate investment trust (REIT)
• Headquarters/country: Denver, United States
• Core markets: US life science, medical office and senior housing real estate
• Key revenue drivers: Rental income from healthcare and life science properties
• Home exchange/listing venue: NYSE (ticker: DOC)
• Trading currency: US dollar (USD)

Healthpeak Properties: core business model

Healthpeak Properties operates as a specialized real estate investment trust focused on healthcare?related properties in the United States. The portfolio is centered on life science campuses, medical office buildings and senior housing facilities, which are typically leased to healthcare providers, research tenants and operators under long?term agreements. As a REIT, the company distributes a substantial portion of its taxable income as dividends to shareholders and relies on a mix of equity and debt to finance acquisitions and development projects.

The business model aims to capture steady rental income from assets that tend to be less cyclical than general commercial real estate, due to the structural demand for healthcare services. Many of Healthpeak Properties’ tenants operate in defensive segments such as outpatient care and research, which can provide resilience through economic cycles. The company’s scale within US healthcare real estate and its concentration in large medical hubs form an important part of its competitive positioning for investors who follow the S&P 500’s income?oriented constituents.

As of mid?May 2026, Healthpeak Properties’ shares were trading at about 19.36 USD, compared with 16.08 USD at the start of the year, representing a gain of roughly 20.4% year to date on the NYSE, according to closing data from MarketBeat as of 05/15/2026. Over the past 52 weeks, the stock traded between 15.70 USD and 19.91 USD, highlighting the recent move toward the upper end of its range as investors reacted to earnings developments and updated analyst views.

Main revenue and product drivers for Healthpeak Properties

Healthpeak Properties generates the bulk of its revenue from rental and related income on leased healthcare properties. Life science assets, which include research and laboratory facilities, represent a key growth area given ongoing investment in biotech and pharmaceutical research. These properties are often located near major US medical and academic centers, and leases can involve specialized build?outs that make tenant relationships relatively sticky. The company also owns medical office buildings serving outpatient care and physician practices, which can provide predictable occupancy rates due to stable patient demand.

In its most recent reported quarter, Healthpeak Properties delivered earnings per share of 0.45 USD, exceeding consensus expectations of 0.43 USD. Revenue in the period increased by 7.1% year over year, supported by portfolio growth and rent escalations, according to data compiled by MarketBeat as of 05/15/2026. For the coming year, Wall Street expects earnings to rise from about 1.75 USD to 1.79 USD per share, implying projected earnings growth of roughly 2.29% over that horizon based on the same source.

Dividends form a central component of the investment case. Market data show that Healthpeak Properties currently offers a dividend yield of around 6.30% at the recent share price, with a price?to?earnings ratio of about 60.50, according to MarketBeat as of 05/15/2026. The relatively high yield reflects the REIT structure and the obligation to distribute a large portion of income, while the elevated P/E multiple suggests investors are paying up for perceived stability in healthcare?linked cash flows despite moderate earnings growth expectations.

Analyst forecasts aggregated by MarketBeat indicate that 15 Wall Street research teams currently cover Healthpeak Properties. Their average 12?month price target stands at 18.92 USD, with estimates ranging from 17.00 USD on the low end to 21.00 USD on the high end, and the consensus rating is classified as “hold,” according to MarketBeat as of 05/15/2026. This implies a modest downside versus the latest closing price yet still reflects a mix of neutral and positive views across the analyst community.

Recent analyst actions and market perception

Recent analyst actions have contributed to renewed attention on Healthpeak Properties within the broader S&P 500 universe. On May 13, 2026, Baird analyst Wesley Golladay raised the firm’s price target on the stock from 19 USD to 21 USD while maintaining an Outperform rating, signaling confidence in the REIT’s ability to deliver attractive risk?adjusted returns, according to a report cited by Insider Monkey as of 05/13/2026. The new target sits at the upper end of the current range of published price objectives.

In contrast, Evercore ISI recently downgraded Healthpeak Properties to an In Line rating from Outperform while simultaneously lifting its price target to 21 USD from 20 USD, based on the same report from Insider Monkey as of 05/13/2026. The move suggests that while Evercore ISI still sees upside to the current trading level, the firm views the stock as more fairly valued relative to the market than before. Together, these differing perspectives illustrate the nuanced debate among analysts around valuation, growth prospects and interest?rate sensitivity.

Consensus data reinforce this balanced view. Of the 15 analysts tracked by MarketBeat, 10 currently assign a hold rating and 5 rate the shares a buy, with no broad conviction in either a strongly bullish or strongly bearish direction, according to MarketBeat as of 05/15/2026. For US investors, this combination of a high current yield, moderate projected earnings growth and largely neutral ratings may position Healthpeak Properties as an income?oriented holding whose performance could hinge on the path of interest rates and demand for healthcare real estate.

Why Healthpeak Properties matters for US investors

Healthpeak Properties is part of the US?listed real estate cohort that offers exposure to the healthcare and life science sectors through property ownership rather than direct operation of medical services. For investors in the United States seeking diversification within their equity portfolios, the stock provides access to long?term demographic trends such as population aging and increased healthcare utilization. Because the shares trade on the NYSE under the ticker DOC and are denominated in US dollars, they can be integrated into domestic portfolios without currency risk.

The company’s presence in the S&P 500 also means that Healthpeak Properties can influence, and be influenced by, flows into index?tracking funds and sector exchange?traded products. In periods when investors favor defensive sectors and income?generating assets, healthcare REITs such as Healthpeak Properties may attract additional attention. Conversely, rising long?term interest rates can weigh on REIT valuations in general as investors reassess the relative appeal of dividend yields versus bond markets. For US income?focused investors, monitoring the spread between Healthpeak Properties’ distribution yield and benchmark Treasury yields may be an important aspect of evaluating the stock’s role in a diversified strategy.

Conclusion

Healthpeak Properties combines a focused healthcare real estate portfolio, a relatively high dividend yield and moderate earnings growth expectations at a time when US investors are closely watching both interest?rate trends and demand for defensive assets. The stock’s year?to?date gain and approach toward the top of its 52?week range reflect optimism following an earnings beat and supportive, if mixed, analyst commentary that includes a higher price target from Baird and a more neutral stance from Evercore ISI. Going forward, the balance between rental growth, capital costs and demographic tailwinds in US healthcare will likely shape how the market values Healthpeak Properties within the broader S&P 500 real estate landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.